donepezil + solifenacin

The combination of donepezil and solifenacin represents a strategic approach to Alzheimer's disease treatment. This combination pairs donepezil, a cholinesterase inhibitor that increases acetylcholine levels in the brain, with solifenacin, an antimuscarinic agent that blocks the peripheral side effects of increased acetylcholine outside the brain. ## Mechanism and Development Donepezil works by inhibiting the acetylcholinesterase enzyme, which normally breaks down acetylcholine in the brain. This inhibition increases acetylcholine levels, helping to improve cognitive function in Alzheimer's patients[8]. However, the increased acetylcholine throughout the body can cause significant side effects, particularly in the gastrointestinal system[2]. Solifenacin is a competitive muscarinic receptor antagonist with high affinity for M3, M1, and M2 receptors[6]. The key innovation of this combination is that solifenacin cannot readily cross the blood-brain barrier, allowing it to block the peripheral effects of increased acetylcholine without interfering with donepezil's beneficial effects in the brain[5][7]. This combination potentially allows for higher dosing of donepezil—up to 400% of standard doses—without the typical side effects that would normally limit dosing[5]. Standard donepezil dosing only achieves about 25-35% CNS cholinesterase inhibition, below the 40-50% considered necessary for optimal cognitive benefit[2].

Brand names

Cognicept

Other names

donepezil/solifenacinCognicept